Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14570422 | 0.86 | OPRK1 (0.70) | OPRK1KCNH2GAA | |
| SCHEMBL5534680 | 0.80 | OPRK1 (0.59) | OPRK1KCNH2 | |
| SCHEMBL5523023 | 0.79 | OPRK1 (0.51) | ALDH1A1OPRK1KCNH2LMNAKMT2A | |
| SCHEMBL28663269 | 0.78 | L3MBTL1 (0.62) | ALDH1A1RAB9ALMNAPKMSLC5A7 | |
| SCHEMBL14570425 | 0.78 | OPRK1 (0.59) | ALDH1A1RAB9AOPRK1KCNH2LMNA | |
| SCHEMBL27889571 | 0.77 | OPRM1 (0.58) | ALDH1A1OPRK1LMNAL3MBTL1KMT2A | |
| SCHEMBL4387098 | 0.74 | L3MBTL1 (0.75) | ALDH1A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL30775258 | 0.73 | EPHX2 (0.50) | ALDH1A1RAB9AOPRK1L3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL27515725 | 0.73 | L3MBTL1 (0.78) | ALDH1A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL3702368 | 0.73 | OPRM1 (0.53) | OPRK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697307-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2014-03-12 | — | — | EP | claimed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | claimed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | claimed |
| EP-1697307-A1 | OPIOID RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-09-06 | — | — | EP | claimed |
| WO-2005061442-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | claimed |
| EP-1697307-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-1697307-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2014-03-12 | — | — | EP | disclosed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
| EP-1697307-A1 | OPIOID RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061442-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010558-A1 | Opioid receptor antagonists | OPRM1, OPRK1, OPRL1 | ALDH1A1 2100/4885RAB9A 1092/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.